Vimian Group AB (publ) (VIMIAN) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the Vimean Group Q4 Report 2025 presentation. During the Q&A session, participants are able to ask questions by dialing pound key five on their telephone keypad. Now I will hand the conference over to the speakers, CEO Alireza Tajbash and CFO Carl Johan Zetterberg-Boudry. Please go ahead. Good morning, everyone, and welcome to Vimean's 2025 year-end and fourth quarter earnings call. I'm Olli Taibach, the new group CEO since the end of last year after leading the veterinary service segment for the past four years. To give you some background, during my four years as head of veterinary services, the business developed from a northern European purchasing organization into a global service platform with over 10,000 member clinics. I personally experienced Vimyans ability to attract talent and entrepreneurs and take something relatively small with potential and build it into global scale and a market leader. I'm a firm believer in our strategy of organic and acquisition driven growth, and we operate in an exciting and resilient industry going through change. I know the sector, the customers, the business and our organization well, and I'm confident about our industry and Vimyans future. We will now go through Vimyon's full year and fourth quarter, and Karl-Johan will later give you deeper insights into the financials. Looking back at full year 2025, Vimyon delivered revenue growth of 13% and adjusted beta growth of 11%. We saw broad-based growth across most of our businesses, not least in specialty pharma, veterinary services, and our med-tech dental businesses. We also put in focused efforts to address the headwinds within medtech orthopedics, in particular in the US. In fall, we received a positive judgment in the US indemnification process, and all counterpa...